Literature DB >> 347642

Fibrinogen--is the benefit worth the risk?

J R Bove.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 347642     DOI： 10.1046/j.1537-2995.1978.18278160573.x

Source DB:  PubMed          Journal:  Transfusion        ISSN： 0041-1132            Impact factor:   3.157


× No keyword cloud information.
  4 in total

1.  Fabrication of growth factor- and extracellular matrix-loaded, gelatin-based scaffolds and their biocompatibility with Schwann cells and dorsal root ganglia.

Authors:  Rodolfo E Gámez Sazo; Katsumi Maenaka; Weiyong Gu; Patrick M Wood; Mary Bartlett Bunge
Journal:  Biomaterials       Date:  2012-08-17       Impact factor: 12.479

2.  Hemostatic properties of a venomic protein in rat organ trauma.

Authors:  Roscoe L Warner; Shannon D McClintock; Adam G Barron; Felix A de la Iglesia
Journal:  Exp Mol Pathol       Date:  2009-09-10       Impact factor: 3.362

3.  Clinical use of blood, blood components and blood products.

Authors:  M A Blajchman; F A Shepherd; R A Perrault
Journal:  Can Med Assoc J       Date:  1979-07-07       Impact factor: 8.262

4.  Time course of haemostatic effects of fibrinogen concentrate administration in aortic surgery.

Authors:  C Solomon; C Hagl; N Rahe-Meyer
Journal:  Br J Anaesth       Date:  2013-02-06       Impact factor: 9.166
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.